SAGE250117C2500
- 2.60
- 0.000.00%
Sage Therapeutics Newsroom
Morgan Stanley Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $9
Hold Rating for SAGE Therapeutics Amid Biogen Acquisition Offer and Pipeline Challenges
RBC Raises Price Target on SAGE Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk
Sage Therapeutics Is Maintained at Overweight by Piper Sandler
Piper Sandler Initiates Sage Therapeutics(SAGE.US) With Buy Rating, Announces Target Price $9
Stifel Maintains Hold on Sage Therapeutics, Lowers Price Target to $6
Sage Therapeutics Analyst Ratings
Stifel Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Cuts Target Price to $6
Mizuho Securities Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Announces Target Price $10
Mizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Agenus (AGEN) and SAGE Therapeutics (SAGE)
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $8 to $14
TD Cowen Maintains Hold on Sage Therapeutics, Lowers Price Target to $9
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $4 to $14
Truist Financial Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
Sage Therapeutics Price Target Maintained With a $4.00/Share by RBC Capital
SAGE Therapeutics: Hold Rating Amid Clinical Setbacks and Strategic Shifts
Wedbush Cuts Price Target on SAGE Therapeutics to $4 From $7, Maintains Neutral Rating
Sage Therapeutics Analyst Ratings
CCORF Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $9